Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Triple-Drug Therapy Promising Against African HIV Subtype

30.12.2004


Triple-drug antiretroviral regimens that are widely used in the United States and Europe against one HIV-1 subtype appear to be effective in South African patients infected with a different HIV-1 subtype who also have tuberculosis (TB) or Kaposi’s sarcoma (KS), according to a study published in the Feb.1 issue of The Journal of Infectious Diseases, now available online. The South African subtype, known as subtype C, is rapidly spreading in developing countries, where TB and KS are major factors in AIDS morbidity and mortality. Since the triple-drug regimens have markedly reduced the morbidity and mortality associated with the subtype that predominates in developed countries (subtype B), the implication is that they may be similarly effective against the C subtype in developing countries as well.



The authors, Edana Cassol and coworkers in Durban, South Africa and the United States, studied 49 patients with previously untreated HIV-1 infection, 21 of whom had pulmonary TB and 28 of whom had KS. Patients in the TB group first received standard TB treatment, then an antiretroviral combination that has been successfully used to treat HIV-1 subtype B infections in patients with active TB--didanosine, lamivudine, and efavirenz, all purchased from Western manufacturers. KS patients received a combination of generic stavudine, lamivudine, and nevirapine, all manufactured in India; some also received cancer chemotherapy. Responses to antiretroviral therapy were measured in part by plasma HIV RNA levels and the number of peripheral blood CD4 cells, which help to orchestrate immune responses.

After three months, 94 percent of the TB group and 80 percent of the Kaposi group had undetectable HIV RNA levels--rates equivalent to or better than those in studies involving Western patients infected with the B subtype. The decrease occurred rapidly during the first 7 days of treatment, then gradually until virus was undetectable--a pattern reported in Western B subtype-infected patients. Similarly, both TB patients and KS patients experienced an early rise in CD4 cell numbers, then a small decrease, followed by a second increase--a pattern also noted in patients treated for subtype B infection.


The investigators concluded that their findings suggest that treatment of C-subtype HIV-1 infections with regimens that have been used against B-subtype infections "will have significant virological and immunological benefit, even in the setting of opportunistic infection and low CD4 counts."

In an accompanying editorial, Timothy P. Flanigan and coworkers in Providence, Rhode Island, Denver, Colorado, and Chennai, India, commented that the findings of this study, along with those of other recent studies, have shattered two myths about treating HIV infection in the developing world: that the benefits obtained in developed countries cannot be replicated in poor settings, and that patients in developing countries are too ill with opportunistic diseases to benefit from antiretroviral therapy. They pointed out, however, that the long-term effects of treatment will need to be demonstrated in further studies by Cassol and coworkers and other investigators.

Steve Baragona | EurekAlert!
Further information:
http://www.idsociety.org

More articles from Health and Medicine:

nachricht GLUT5 fluorescent probe fingerprints cancer cells
20.04.2018 | Michigan Technological University

nachricht Scientists re-create brain neurons to study obesity and personalize treatment
20.04.2018 | Cedars-Sinai Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Spider silk key to new bone-fixing composite

University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

Im Focus: Gamma-ray flashes from plasma filaments

Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.

The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...

Im Focus: Basel researchers succeed in cultivating cartilage from stem cells

Stable joint cartilage can be produced from adult stem cells originating from bone marrow. This is made possible by inducing specific molecular processes occurring during embryonic cartilage formation, as researchers from the University and University Hospital of Basel report in the scientific journal PNAS.

Certain mesenchymal stem/stromal cells from the bone marrow of adults are considered extremely promising for skeletal tissue regeneration. These adult stem...

Im Focus: Like a wedge in a hinge

Researchers lay groundwork to tailor drugs for new targets in cancer therapy

In the fight against cancer, scientists are developing new drugs to hit tumor cells at so far unused weak points. Such a “sore spot” is the protein complex...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur

09.04.2018 | Event News

 
Latest News

Magnetic nano-imaging on a table top

20.04.2018 | Physics and Astronomy

Start of work for the world's largest electric truck

20.04.2018 | Interdisciplinary Research

Atoms may hum a tune from grand cosmic symphony

20.04.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>